Loading...

Cellectis

ENXTPA:ALCLS
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALCLS
ENXTPA
€716M
Market Cap
  1. Home
  2. FR
  3. Pharmaceuticals & Biotech
Company description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The last earnings update was 11 days ago. More info.


Add to Portfolio Compare Print
ALCLS Share Price and Events
7 Day Returns
1.5%
ENXTPA:ALCLS
1.5%
FR Biotechs
1.9%
FR Market
1 Year Returns
-32.6%
ENXTPA:ALCLS
-33.5%
FR Biotechs
-2.3%
FR Market
ALCLS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cellectis (ALCLS) 1.5% -3.8% 7.2% -32.6% -37.5% 204.1%
FR Biotechs 1.5% -2.5% 2.9% -33.5% -50.4% -32.4%
FR Market 1.9% -2.3% 5.9% -2.3% 30.8% 29.8%
1 Year Return vs Industry and Market
  • ALCLS underperformed the Market in France which returned -2.3% over the past year.
Price Volatility
ALCLS
Industry
5yr Volatility vs Market
Related Companies

ALCLS Value

 Is Cellectis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cellectis. This is due to cash flow or dividend data being unavailable. The share price is €16.88.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cellectis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cellectis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:ALCLS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.62
ENXTPA:ALCLS Share Price ** ENXTPA (2019-05-17) in EUR €16.88
ENXTPA:ALCLS Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.116 $18.84
France Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 18.19x
France Market PE Ratio Median Figure of 418 Publicly-Listed Companies 17.81x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cellectis.

ENXTPA:ALCLS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALCLS Share Price ÷ EPS (both in USD)

= 18.84 ÷ -1.62

-11.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cellectis is loss making, we can't compare its value to the FR Biotechs industry average.
  • Cellectis is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does Cellectis's expected growth come at a high price?
Raw Data
ENXTPA:ALCLS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
61.1%per year
France Biotechs Industry PEG Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 0.34x
France Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cellectis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cellectis's assets?
Raw Data
ENXTPA:ALCLS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $9.22
ENXTPA:ALCLS Share Price * ENXTPA (2019-05-17) in EUR €16.88
ENXTPA:ALCLS Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.116 $18.84
France Biotechs Industry PB Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 2.33x
France Market PB Ratio Median Figure of 619 Publicly-Listed Companies 1.44x
ENXTPA:ALCLS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALCLS Share Price ÷ Book Value per Share (both in USD)

= 18.84 ÷ 9.22

2.04x

* Primary Listing of Cellectis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cellectis is good value based on assets compared to the FR Biotechs industry average.
X
Value checks
We assess Cellectis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cellectis has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ALCLS Future Performance

 How is Cellectis expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cellectis expected to grow at an attractive rate?
  • Cellectis's earnings growth is expected to exceed the low risk savings rate of 0.7%.
Growth vs Market Checks
  • Cellectis's earnings growth is expected to exceed the France market average.
  • Cellectis's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
Raw Data
ENXTPA:ALCLS Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTPA:ALCLS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 61.1%
ENXTPA:ALCLS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 66.4%
France Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 32.7%
France Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 39.4%
France Market Earnings Growth Rate Market Cap Weighted Average 13.2%
France Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:ALCLS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:ALCLS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 493 -33 224 5
2022-12-31 251 -69 44 5
2021-12-31 94 -72 -104 8
2020-12-31 46 -49 -113 10
2019-12-31 21 -119 -108 10
ENXTPA:ALCLS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 17 -71 -69
2018-12-31 21 -68 -79
2018-09-30 26 -57 -83
2018-06-30 31 -58 -86
2018-03-31 31 -56 -105
2017-12-31 34 -52 -99
2017-09-30 40 -41 -86
2017-06-30 45 -74
2017-03-31 57 -28 -56
2016-12-31 56 -33 -67
2016-09-30 76 -6 -45
2016-06-30 74 -45

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cellectis's earnings are expected to grow significantly at over 20% yearly.
  • Cellectis's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:ALCLS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Cellectis Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ALCLS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -2.65 -2.65 -2.65 1.00
2019-12-31 -2.77 -2.77 -2.77 1.00
ENXTPA:ALCLS Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.62
2018-12-31 -1.93
2018-09-30 -2.11
2018-06-30 -2.29
2018-03-31 -2.93
2017-12-31 -2.78
2017-09-30 -2.41
2017-06-30 -2.08
2017-03-31 -1.57
2016-12-31 -1.91
2016-09-30 -1.27
2016-06-30 -1.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cellectis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cellectis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cellectis has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ALCLS Past Performance

  How has Cellectis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cellectis's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cellectis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cellectis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cellectis's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cellectis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cellectis Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ALCLS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 16.80 -68.50 44.72 72.68
2018-12-31 21.43 -78.69 47.25 76.57
2018-09-30 25.61 -82.60 49.74 75.04
2018-06-30 30.84 -85.89 50.26 76.65
2018-03-31 31.49 -105.04 49.03 77.24
2017-12-31 33.72 -99.37 44.75 78.43
2017-09-30 39.69 -85.62 44.18 78.71
2017-06-30 44.89 -73.58 41.83 73.84
2017-03-31 56.57 -55.52 41.89 77.86
2016-12-31 56.44 -67.26 43.41 78.46
2016-09-30 76.26 -44.64 40.16 76.29
2016-06-30 74.33 -44.87 38.01 78.59
2016-03-31 64.54 -63.95 36.91 72.71
2015-12-31 62.57 -22.80 30.22 58.15
2015-09-30 39.38 -28.00 25.22 44.35
2015-06-30 37.20 -9.61 21.32 30.02
2015-03-31 32.80 12.10 16.51 19.34
2014-12-31 32.02 3.44 15.87 17.44
2014-09-30 27.93 -8.06 16.47 19.17
2014-06-30 24.38 -21.37 17.78 21.86
2014-03-31 21.04 -28.54 20.89 23.30
2013-12-31 17.52 -35.56 23.87 24.57
2013-09-30 14.99 -32.84 22.95 21.75
2013-06-30 18.31 -31.24 25.14 20.99
2013-03-31 19.52 -28.58 23.13 21.34
2012-12-31 21.60 -27.13 22.11 22.63
2012-09-30 23.75 -30.01 25.15 22.15
2012-06-30 20.23 -31.49 24.89 19.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cellectis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cellectis has efficiently used its assets last year compared to the FR Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cellectis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cellectis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cellectis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ALCLS Health

 How is Cellectis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cellectis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cellectis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cellectis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cellectis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 12.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cellectis Company Filings, last reported 1 month ago.

ENXTPA:ALCLS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 432.31 35.65 421.46
2018-12-31 450.27 1.35 451.89
2018-09-30 471.32 0.29 475.91
2018-06-30 488.77 1.00 491.09
2018-03-31 276.74 0.35 282.06
2017-12-31 283.99 0.03 296.98
2017-09-30 300.14 0.04 304.10
2017-06-30 270.72 0.05 271.09
2017-03-31 271.53 0.06 276.44
2016-12-31 274.67 0.07 291.16
2016-09-30 286.70 2.15 296.71
2016-06-30 284.33 2.14 299.54
2016-03-31 280.09 2.22 314.92
2015-12-31 286.31 2.16 341.28
2015-09-30 267.36 3.41 311.76
2015-06-30 270.92 3.48 316.23
2015-03-31 280.24 0.57 127.18
2014-12-31 72.05 4.46 135.99
2014-09-30 75.13 4.65 141.79
2014-06-30 20.13 5.48 27.67
2014-03-31 20.26 5.52 27.85
2013-12-31 3.47 5.60 10.41
2013-09-30 3.41 5.50 10.23
2013-06-30 56.19 5.85 12.41
2013-03-31 55.38 5.77 12.23
2012-12-31 70.47 5.67 28.75
2012-09-30 78.99 5.51 28.01
2012-06-30 90.66 5.50 35.29
  • Cellectis's level of debt (8.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (27.2% vs 8.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cellectis has sufficient cash runway for more than 3 years based on current free cash flow.
  • Cellectis has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 34.5% each year.
X
Financial health checks
We assess Cellectis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cellectis has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ALCLS Dividends

 What is Cellectis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cellectis dividends.
If you bought €2,000 of Cellectis shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cellectis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cellectis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:ALCLS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
France Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3.1%
France Minimum Threshold Dividend Yield 10th Percentile 1%
France Bottom 25% Dividend Yield 25th Percentile 1.6%
France Top 25% Dividend Yield 75th Percentile 4.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:ALCLS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cellectis has not reported any payouts.
  • Unable to verify if Cellectis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cellectis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cellectis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cellectis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cellectis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cellectis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ALCLS Management

 What is the CEO of Cellectis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
André Choulika
COMPENSATION $342,400
AGE 53
TENURE AS CEO 20.3 years
CEO Bio

Dr. André Choulika, Ph.D. is the Founder of Cellectis SA and has been its Chief Executive Officer since 1999 and as its Chairman since June 27, 2011. Dr. Choulika is a pioneer in the analysis and use of Meganucleases to modify complex genomes. Dr. Choulika has made many of the critical observations in the field and is an author of the most significant patents on the use of Meganucleases in vivo. He has been Chairman of Calyxt, Inc. since August 2010. He serves as the Chairman of France Biotech. He serves as a Director of Cellectis SA. He serves as President of Calyxt, Inc. since August 2010. Dr. Choulika is a Member of Investment Committee at G1J Ile-de-France SA, SCR. He received a Ph.D. in Molecular Virology from the University of Paris VI / Institut Pasteur. Dr. Choulika has made post-doctoral studies at the Harvard Medical School within the department of Molecular Medicine of Boston's Children's Hospital.

CEO Compensation
  • Insufficient data for André to compare compensation growth.
  • André's remuneration is lower than average for companies of similar size in France.
Management Team Tenure

Average tenure and age of the Cellectis management team in years:

4.8
Average Tenure
46.5
Average Age
  • The tenure for the Cellectis management team is about average.
Management Team

André Choulika

TITLE
Co-Founder
COMPENSATION
$342K
AGE
53
TENURE
20.3 yrs

David J. Sourdive

TITLE
Co-Founder
COMPENSATION
$262K
AGE
51

Eric Dutang

TITLE
Chief Financial Officer
AGE
44
TENURE
3.3 yrs

Elsy Boglioli

TITLE
Chief Operating Officer
AGE
36
TENURE
1.2 yrs

Jean Epinat

TITLE
Chief Technological Officer

Philippe Duchateau

TITLE
Chief Scientific Officer
AGE
55
TENURE
7.3 yrs

Stephan Reynier

TITLE
Chief Regulatory & Compliance Officer
AGE
49

Marie-Bleuenn Terrier

TITLE
General Counsel
AGE
36
TENURE
6.3 yrs

Jennifer Moore

TITLE
Vice President of Communications

Stéphane Dépil

TITLE
Senior VP of Research & Development and Chief Medical Officer
AGE
43
TENURE
1.4 yrs
Board of Directors Tenure

Average tenure and age of the Cellectis board of directors in years:

8
Average Tenure
59
Average Age
  • The tenure for the Cellectis board of directors is about average.
Board of Directors

André Choulika

TITLE
Co-Founder
COMPENSATION
$342K
AGE
53
TENURE
8.3 yrs

David J. Sourdive

TITLE
Co-Founder
COMPENSATION
$262K
AGE
51
TENURE
19.3 yrs

Alain Fischer

TITLE
Member of Medical Advisory Board

Alain Godard

TITLE
Independent Director
AGE
72
TENURE
11.6 yrs

Laurent Arthaud

TITLE
Independent Director
AGE
55
TENURE
7.6 yrs

Annick Schwebig

TITLE
Independent Director
AGE
67
TENURE
7.6 yrs

Pierre Bastid

TITLE
Independent Director
AGE
63
TENURE
7.6 yrs

Pascale Augé

TITLE
Advisor & Non-Voting Director

Véronique Leblond

TITLE
Member of Medical Advisory Board

David Linch

TITLE
Member of Medical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Cellectis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cellectis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ALCLS News

Simply Wall St News

What Type Of Shareholder Owns Cellectis S.A.'s (EPA:ALCLS)?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Companies that have been privatized tend to have low insider ownership. … Cellectis isn't enormous, but it's not particularly small either.

Simply Wall St -

Shareholders Are Thrilled That The Cellectis (EPA:ALCLS) Share Price Increased 220%

Because Cellectis is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. … In comparison, the share price rise of 26% per year over the last half a decade is pretty impressive.

Simply Wall St -

Does The Cellectis S.A. (EPA:ALCLS) Share Price Tend To Follow The Market?

In finance, Beta is a measure of volatility. … Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility).

Simply Wall St -

What Type Of Shareholder Owns Cellectis S.A.'s (EPA:ALCLS)?

Generally speaking, as a company grows, institutions will increase their ownership. … Taking a look at the our data on the ownership groups (below), it's seems that. … institutional investors have bought into the company.

Simply Wall St -

Is Cellectis SA's (EPA:ALCLS) CEO Incentives Align With Yours?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … At the time of writing our data says that Cellectis SA has a market cap of €1.0b, and is paying total annual CEO compensation of US$342k. … Most shareholders would consider it a positive that André Choulika takes less compensation than the CEOs of most similar size companies, leaving more for shareholders.

Simply Wall St -

Is Cellectis SA (EPA:ALCLS) A Volatile Stock?

Volatility is considered to be a measure of risk in modern finance theory. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

What Should We Expect From Cellectis SA.'s (EPA:ALCLS) Earnings In The Next Couple Of Years?

The most recent earnings update Cellectis SA.'s (ENXTPA:ALCLS) released in December 2017 confirmed company earnings became less negative compared to the previous year's level as a result of recent tailwinds Below is a brief commentary on my key takeaways on how market analysts perceive Cellectis's earnings growth outlook over the next few years and whether the future looks brighter. … ENXTPA:ALCLS Future Profit Apr 27th 18 Although it’s useful to understand the growth rate year by year relative to today’s value, it may be more beneficial to determine the rate at which the earnings are growing every year, on average. … Future Earnings: How does ALCLS's growth rate compare to its peers and the wider market?

Simply Wall St -

Where Cellectis SA.'s (EPA:ALCLS) Earnings Growth Stands Against Its Industry

After looking at Cellectis SA.'s (ENXTPA:ALCLS) latest earnings announcement (31 December 2017), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … ENXTPA:ALCLS Income Statement Mar 26th 18 We can further examine Cellectis's loss by looking at what the industry has been experiencing over the past few years. … Looking at growth from a sector-level, the FR biotechs industry has been multiplying growth, more than doubling average earnings in the past year, and a more muted 6.22% over the past half a decade.

Simply Wall St -

Analysts Expect Breakeven For Cellectis SA. (EPA:ALCLS)

In this article, I will touch on the expectations for ALCLS’s growth and when analysts expect the company to become profitable. … How fast will ALCLS have to grow each year in order to reach the breakeven point by 2020? … Next Steps: There are too many aspects of ALCLS to cover in one brief article, but the key fundamentals for the company can all be found in one place – ALCLS’s company page on Simply Wall St.

Simply Wall St -

ALCLS Company Info

Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.

Details
Name: Cellectis S.A.
ALCLS
Exchange: ENXTPA
Founded: 1999
€716,219,564
42,430,069
Website: http://www.cellectis.com
Address: Cellectis S.A.
8, rue de la Croix Jarry,
Paris,
Ile-de-France, 75013,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALCLS Ordinary Shares Euronext Paris FR EUR 07. Feb 2007
OTCPK CMVL.F Ordinary Shares Pink Sheets LLC US USD 07. Feb 2007
DB ZVA Ordinary Shares Deutsche Boerse AG DE EUR 07. Feb 2007
LSE 0WA2 Ordinary Shares London Stock Exchange GB EUR 07. Feb 2007
NasdaqGM CLLS SPONSORED ADS Nasdaq Global Market US USD 26. Mar 2015
DB ZVAA SPONSORED ADS Deutsche Boerse AG DE EUR 26. Mar 2015
Number of employees
Current staff
Staff numbers
166
Cellectis employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/19 21:20
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/14
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.